Neuphoria Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Neuphoria Therapeutics Inc. (NEUP) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $781.90 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-09-18
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $4.20K, a 99.61% decline year-over-year.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $157.90K.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $570.58K.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $49.22K, a 91.59% decline year-over-year.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2026 was $781.90K, a 363.95% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $168.53K, a 272.95% increase from fiscal 2024.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $45.19K.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$1.04M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $162.09K derived: sum of 2 quarters · filed 2026-09-18 | $732.67K derived: sum of 3 quarters · filed 2026-09-18 | $781.90K 10-K · filed 2026-09-18 |
| 2026-03-31 | $157.90K 10-Q · filed 2026-05-15 | $728.48K derived: sum of 2 quarters · filed 2026-05-15 | $777.70K 10-Q · filed 2026-05-15 | $1.85M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $570.58K 10-Q · filed 2026-02-17 | $619.80K 10-Q · filed 2026-02-17 | $1.69M derived: sum of 3 quarters · filed 2026-09-18 | $1.49M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $49.22K 10-Q · filed 2025-11-14 | $1.12M derived: sum of 2 quarters · filed 2026-09-18 | $920.80K derived: sum of 3 quarters · filed 2026-09-18 | -$367.63K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $871.58K derived: sum of 2 quarters · filed 2026-09-18 | -$416.85K derived: sum of 3 quarters · filed 2026-09-18 | $168.53K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$195.82K 10-Q · filed 2026-05-15 | -$1.48M derived: sum of 2 quarters · filed 2026-05-15 | -$898.87K 10-Q · filed 2026-05-15 | -$679.35K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$1.29M 10-Q · filed 2026-02-17 | -$703.05K 10-Q · filed 2026-02-17 | -$483.53K derived: sum of 3 quarters · filed 2026-02-17 | -$1.05M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $585.38K 10-Q · filed 2025-11-14 | $804.90K derived: sum of 2 quarters · filed 2025-11-14 | $242.95K derived: sum of 3 quarters · filed 2025-11-14 | $694.04K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $219.52K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$342.43K derived: sum of 2 quarters · filed 2025-09-29 | $108.66K derived: sum of 3 quarters · filed 2025-09-29 | $45.19K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$561.95K 10-Q · filed 2025-05-20 | -$110.86K derived: sum of 2 quarters · filed 2025-05-20 | -$174.33K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $451.08K 10-Q · filed 2025-02-14 | $387.62K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$63.47K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$1.04M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |